Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
DAPH is a phthalimide with diverse biological activities.1,2,3,4 It is an EGFR inhibitor that selectively inhibits the EGFR intracellular kinase domain over v-Abl, c-Src, PKCα, PKCβ1, PKCβ2, and PKCγ (IC50s = 0.3, >50, 16, 6, 30, 4.8, and 30 μM, respectively) and a panel of 11 other kinases.1 It also inhibits EGFR autophosphorylation in A431 human epidermoid carcinoma cell membranes and intact cells (IC50s = 1 and <10 μM, respectively). DAPH inhibits contractions induced by phenylephrine (Item No. 17205) in isolated rat endothelium-denuded aortic rings in a concentration-dependent manner.2 It inhibits aggregation of amyloid-β (1-42) (Aβ42) peptide (Item No. 20574), disaggregates preformed Aβ42 fibrils, and inhibits calcium influx into mouse CATH.a neuronal cells when used at a concentration of 10 μM.3 DAPH also inhibits aggregation of a Sup35 yeast prion protein fragment that contains its N-terminal and highly charged middle domains (IC50 = 0.58 μM).4
The information regarding the kinase IC50 values and reduction in EGFR autophosphorylation was drawn from a paper that has been retracted; however, the information specified in the retraction statement has not been included.1
WARNING This product is not for human or veterinary use.
1. 4,5-
2. α1-
3. Efficient reversal of Alzheimer’s disease fibril formation and elimination of neurotoxicity by a small molecule. Proc. Natl. Acad. Sci. USA 101(40), 14326-14332 (2004).
4. Direct and selective elimination of specific prions and amyloids by 4,5-